Académique Documents
Professionnel Documents
Culture Documents
2 ● Monitor intake and output ratios and daily weight. Assess patient for signs and
symptoms of dehydration (decreased thirst, lethargy, hemoconcentration), espe-
antihistamines, opioid analgesics, and sedative/hypnotics. Concurrent use cially in geriatric patients. PDF Page #2
with epinephrine may result in severe hypotension and tachycardia. Maypthera- ● Assess fluid intake and bowel function. Increased bulk and fluids in the diet help
peutic effects of levodopa. Acute encephalopathic syndrome may occur when used minimize constipating effects.
with lithium. Dementia may occur with methyldopa. ● Monitor patient for onset of akathisia (restlessness or desire to keep moving),
Drug-Natural Products: Kava-kava, valerian, or chamomile canqCNS de- which may appear within 6 hr of 1st dose and may be difficult to distinguish from
pression. psychotic agitation. Benztropine may be used to differentiate agitation from akath-
isia. Observe closely for extrapyramidal side effects (parkinsonian— difficulty
Route/Dosage speaking or swallowing, loss of balance control, pill rolling of hands, mask-like
Haloperidol face, shuffling gait, rigidity, tremors; and dystonic— muscle spasms, twisting mo-
PO (Adults): 0.5– 5 mg 2– 3 times daily. Patients with severe symptoms may require tions, twitching, inability to move eyes, weakness of arms or legs). Trihexypheni-
up to 100 mg/day. dyl or benzotropine may be used to control these symptoms. Benzodiazepines may
PO (Geriatric Patients or Debilitated Patients): 0.5– 2 mg twice daily initially; alleviate akathisia.
may be graduallyqas needed. ● Monitor for tardive dyskinesia (uncontrolled rhythmic movement of mouth, face,
PO (Children 3– 12 yr or 15– 40 kg): 0.25– 0.5 mg/day given in 2– 3 divided and extremities; lip smacking or puckering; puffing of cheeks; uncontrolled
doses; increase by 0.25– 0.5 mg every 5– 7 days; maximum dose: 0.15 mg/kg/day chewing; rapid or worm-like movements of tongue, excessive eye blinking). Re-
(up to 0.75 mg/kg/day for Tourette’s syndrome or 0.15 mg/kg/day for psychoses). port immediately; may be irreversible.
IM (Adults): 2– 5 mg q 1– 8 hr (not to exceed 100 mg/day). ● Monitor for symptoms related to hyperprolactinemia (menstrual abnormalities,
IM (Children 6– 12 yr): 1– 3 mg/dose every 4– 8 hours to a maximum of 0.15 mg/ galactorrhea, sexual dysfunction).
kg/day. ● Monitor for development of neuroleptic malignant syndrome (fever,
IV (Adults): 0.5– 5 mg, may be repeated q 30 min (unlabeled). respiratory distress, tachycardia, seizures, diaphoresis, hypertension
or hypotension, pallor, tiredness, severe muscle stiffness, loss of blad-
Haloperidol Decanoate der control). Report symptoms immediately. May also cause leukocyto-
IM (Adults): 10– 15 times the previous daily PO dose but not to exceed 100 mg ini- sis, elevated liver function tests, elevated CPK.
tially, given monthly (not to exceed 300 mg/mo). ● Lab Test Considerations: Monitor CBC with differential and liver func-
tion tests periodically during therapy.
NURSING IMPLICATIONS ● Monitor serum prolactin prior to and periodically during therapy. May causeqse-
Assessment rum prolactin levels.
● Assess mental status (orientation, mood, behavior) prior to and periodically dur-
ing therapy.
Potential Nursing Diagnoses
Disturbed thought process (Indications)
● Assess positive (hallucination, delusions) and negative (social isolation) symp-
Disturbed sensory perception (specify: visual, auditory, kinesthetic, gustatory, tactile,
toms of schizophrenia.
olfactory) (Indications)
● Monitor BP (sitting, standing, lying) and pulse prior to and frequently during the
period of dose adjustment. May cause QT interval changes on ECG. Implementation
● Observe patient carefully when administering medication, to ensure that medica- ● Avoid skin contact with oral solution; may cause contact dermatitis.
tion is actually taken and not hoarded. ● PO: Administer with food or full glass of water or milk to minimize GI irritation.
䉷 2015 F.A. Davis Company CONTINUED
Name /bks_53161_deglins_md_disk/haloperidol 03/07/2014 08:27AM Plate # 0-Composite pg 3 # 3
4
Evaluation/Desired Outcomes PDF Page #4
● Decrease in hallucinations, insomnia, agitation, hostility, and delusions.
● Decreased tics and vocalization in Tourette’s syndrome.
● Improved behavior in children with severe behavioral problems. If no therapeutic
effects are seen in 2– 4 wk, dosage may be increased.
Why was this drug prescribed for your patient?